Media headlines about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alimera Sciences earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 86 out of 100, meaning that recent media coverage is very likely to have an effect on the company’s share price in the next few days.
These are some of the news stories that may have impacted Accern’s scoring:
- Alimera Sciences, Inc. (ALIM): Scrutinizing the Chart – Economic News (economicsandmoney.com)
- Alimera Sciences’ CEO Dan Myers to Present US Real-World ILUVIEN® Post-Marketing Data During Ophthalmology … – GlobeNewswire (press release) (globenewswire.com)
- North America Will Remain Dominant in the Global Diabetic Macular Edema Market (medindia.net)
- Alimera Sciences’ CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017 (finance.yahoo.com)
- HC Wainwright Reiterates “$5.00” Price Target for Alimera Sciences, Inc. (NASDAQ:ALIM) (americanbankingnews.com)
Several analysts have recently weighed in on the stock. ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Zacks Investment Research downgraded shares of Alimera Sciences from a “buy” rating to a “hold” rating in a report on Thursday, July 13th. HC Wainwright set a $5.00 target price on shares of Alimera Sciences and gave the company a “buy” rating in a report on Friday. Cowen and Company set a $3.00 target price on shares of Alimera Sciences and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Rodman & Renshaw assumed coverage on shares of Alimera Sciences in a report on Thursday, April 27th. They issued a “buy” rating and a $4.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $3.38.
Shares of Alimera Sciences (ALIM) traded down 1.92% during mid-day trading on Tuesday, hitting $1.53. 259,605 shares of the company traded hands. Alimera Sciences has a 52-week low of $1.03 and a 52-week high of $1.87. The firm’s market cap is $99.30 million. The firm has a 50-day moving average price of $1.43 and a 200 day moving average price of $1.39.
Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million for the quarter, compared to the consensus estimate of $10.20 million. During the same quarter last year, the business posted ($0.17) EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities research analysts anticipate that Alimera Sciences will post ($0.21) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/08/08/somewhat-positive-news-coverage-very-likely-to-affect-alimera-sciences-nasdaqalim-stock-price-updated-updated-updated.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.